XML 106 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 22,196,097 $ 23,693,633
Short-term investments 67,338,017 57,538,852
Accounts receivable 700,073 3,316,361
Accounts receivable from affiliated entities 1,332,044 738,583
Prepaid expenses and other current assets 1,584,598 1,406,590
Prepaid expenses and other current assets from affiliated entities 1,050,140 1,120,805
Total current assets 94,200,969 87,814,824
Fixed assets, net 12,773,017 15,949,014
Investments in affiliated entities 6,315,356 9,405,913
Intangible assets, net 3,693,851 4,760,145
Goodwill 10,513,371 10,513,371
Operating lease right-of-use assets 13,783,009  
Other assets 2,672,024 2,669,998
Total assets 143,951,597 131,113,265
Current liabilities:    
Accounts payable and accrued expenses 18,237,258 23,134,733
Accounts payable and accrued expenses due to affiliated entities 729,729 977,792
Accrued clinical trial expenses 4,049,727 5,671,764
Deferred revenue 92,353 223,577
Deferred revenue from affiliated entities 31,775 33,575
Deferred rent 0 1,065,387
Operating lease liability 2,074,842 0
Grant funding liability 6,065,212 4,165,848
Grant funding liability from affiliated entities 708,425 27,083
Total current liabilities 31,989,321 35,299,759
Deferred revenue, net of current portion 101,567 150,793
Derivative liability 8,819,023 0
Deferred rent, net of current portion 0 8,518,207
Operating lease liability, net of current portion 20,409,922  
Deferred tax liabilities 32,046 24,766
Grant funding liability from affiliated entity, net of current portion 135,000 0
Other liabilities 36,943 87,333
Total liabilities 138,546,739 44,080,858
Commitments and contingencies
Inovio Pharmaceuticals, Inc. stockholders’ equity:    
Preferred stock—par value $0.001; Authorized shares: 10,000,000, issued and outstanding shares: 23 at December 31, 2019 and December 31, 2018 0 0
Common stock—par value $0.001; Authorized shares: 600,000,000 at December 31, 2019 and December 31, 2018, issued and outstanding: 101,361,034 at December 31, 2019 and 97,225,810 at December 31, 2018 101,361 97,226
Additional paid-in capital 742,646,785 707,794,215
Accumulated deficit (739,785,655) (620,426,436)
Accumulated other comprehensive income (loss) 472,608 (528,867)
Total Inovio Pharmaceuticals, Inc. stockholders’ equity 3,435,099 86,936,138
Non-controlling interest 1,969,759 96,269
Total stockholders’ equity 5,404,858 87,032,407
Total liabilities and stockholders’ equity 143,951,597 131,113,265
6.50% Convertible Senior Notes Due 2024    
Current liabilities:    
Convertible debt 64,180,325 0
Convertible Bonds    
Current liabilities:    
Convertible debt $ 12,842,592 $ 0